MAP3K7 and metabolic dysfunction-associated steatohepatitis: Consistently, the serum contents of pro‐inflammatory cytokines, hepatic function indicators, activated liver Zdhhc3, and a significant increase in pan‐palmitoylation contents along with Irhom2‐Map3k7 signaling axis were markedly suppressed by dose‐dependent 2‐BP treatment in the context of NASH (Figure S18c–f, Supporting Information).